Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.67 USD | +3.78% | -1.68% | -10.71% |
May. 06 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 29 | North American Morning Briefing : Investors Brace -2- | DJ |
Financials (USD)
Sales 2021 | 172M | Sales 2022 | 317M | Capitalization | 380M |
---|---|---|---|---|---|
Net income 2021 | -8M | Net income 2022 | 35M | EV / Sales 2021 | 3.44 x |
Net cash position 2021 | 67.84M | Net Debt 2022 | 10.19M | EV / Sales 2022 | 1.23 x |
P/E ratio 2021 |
-77
x | P/E ratio 2022 |
10.7
x | Employees | 134 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 65.14% |
Latest transcript on Eagle Pharmaceuticals, Inc.
1 day | +3.78% | ||
1 week | -1.68% | ||
Current month | +14.18% | ||
1 month | +1.74% | ||
3 months | -11.05% | ||
6 months | -48.51% | ||
Current year | -10.71% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Graves
CEO | Chief Executive Officer | 61 | 13-10-31 |
Steven B. Ratoff
DFI | Director of Finance/CFO | 81 | 07-02-28 |
Ryan Debski
CMP | Compliance Officer | - | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven B. Ratoff
DFI | Director of Finance/CFO | 81 | 07-02-28 |
Jennifer Simpson
BRD | Director/Board Member | 55 | 19-08-27 |
Richard Edlin
BRD | Director/Board Member | 63 | 17-03-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.54% | 28 M€ | -0.48% | ||
0.25% | 25 M€ | -1.82% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 4.67 | +3.78% | 62,535 |
24-05-13 | 4.5 | -0.88% | 246,295 |
24-05-10 | 4.54 | -2.58% | 122,646 |
24-05-09 | 4.66 | -1.89% | 51,642 |
24-05-08 | 4.75 | 0.00% | 69,831 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-10.71% | 58.44M | |
+9.85% | 72.5B | |
+11.03% | 9.11B | |
-12.85% | 5.07B | |
+60.16% | 5.01B | |
+1.60% | 3.85B | |
-19.20% | 2.46B | |
+18.65% | 2.44B | |
+24.62% | 2.27B | |
-27.46% | 2.26B |
- Stock Market
- Equities
- EGRX Stock